Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.43 |
| ▸ | NPY1R | P25929 | 11/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPY4R | P50391 | 2/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.40 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.39 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.39 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8112679 | 0.82 | NPY1R (0.58) | NPY1RNPY4RNPY5RNPFFR1NPFFR2 | |
| SCHEMBL29590479 | 0.77 | QRFPR (0.53) | NPY1RNPY4RNPY5RQRFPR | |
| SCHEMBL4283125 | 0.76 | EPHX2 (0.38) | F10NPY1RNPY4RNPY5RQRFPR | |
| SCHEMBL29590985 | 0.76 | QRFPR (0.56) | NPY1RNPY4RNPY5RQRFPR | |
| SCHEMBL29591802 | 0.76 | QRFPR (0.54) | NPY1RNPY4RNPY5RQRFPR | |
| SCHEMBL30121028 | 0.76 | QRFPR (0.56) | NPY1RNPY4RNPY5RQRFPR | |
| SCHEMBL16181288 | 0.75 | NPY1R (0.56) | F2NPY1R | |
| SCHEMBL29875551 | 0.75 | C3AR1 (0.40) | NPY1RNPY4RNPY5RQRFPR | |
| SCHEMBL21883428 | 0.75 | QRFPR (0.55) | NPY1RNPY4RNPY5RQRFPR | |
| SCHEMBL7751683 | 0.75 | NPY1R (0.62) | NPY1RNPY4RNPY5RNPFFR1NPFFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181569-A1 | COMPOSITIONS AND METHODS TO TREAT POLYCYSTIC KIDNEY DISEASE | UNIV LOUISIANA STATE (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181569-A1 | COMPOSITIONS AND METHODS TO TREAT POLYCYSTIC KIDNEY DISEASE | OPRK1, OPRL1, AVPR1A | F10 2610/4885PRSS1 1694/4885F2 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.